| Name | Title | Contact Details |
|---|
Micromet, Inc is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Inceptor Bio is developing multiple next-generation cell therapy platforms to cure difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment.
Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines do not readily address.
Depomed is a leading specialty pharmaceutical company committed to putting the Patient First in everything we do; with a focus on enhancing the lives of patients, families, physicians, providers and in payors through commercialization of products in the areas of pain and neurology, and developing drugs in areas of unmet medical needs. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain Business and has an emerging Specialty Business focused on orphan drug indications and areas of unmet medical need. Depomed has a clear THREE PILLAR strategy for growth: MAINTAIN a strong/profitable NUCYNTA franchise through a commercialization agreement with Collegium, GROW the Neurology and Pain Business and BUILD a new Specialty Business through a recent Cosyntropin transaction. The company`s strategy is to continue to identify, license and develop new products-that offer enhanced therapeutic options to patient populations that may be underserved by existing therapies. As part of the transformation strategy, Depomed will be relocating its headquarters out of California. Information about location will be shared during the interview process. Depomed is listed on the NASDAQ market under the ticker DEPO. Depomed is an AA/EEO/Veterans/Disabled employer.
San Diego-based Biocept, Inc. (Nasdaq: BIOC) develops and performs diagnostic assays that provide clinically actionable information to improve outcomes for patients with a variety of cancers. Biocept`s unique combination of cell-based and cell-free DNA analysis allows us to rapidly detect and monitor certain cancer biomarkers in blood and cerebrospinal fluid (CSF). Our patented Target Selector™ technology quantitatively analyzes tumor cells for tumor-associated biomarkers, offering high sensitivity and specificity compared with methods currently used by other laboratories. In addition to our broad portfolio of blood-based liquid biopsy tests, we offer the CNSide™ CSF assay, which addresses an unmet clinical need for patients with cancer that has metastasized to the central nervous system. Between 10% and 30% of patients with cancer will develop brain or spinal cord metastasis. Survival is often low, and few are diagnosed early enough for effective therapeutic intervention. CNSide answers three key questions: Is there a tumor? Is there a target for treatment? Is there a trend in treatment response? We offer diagnostic laboratory services for oncologists, pathologists, hospitals, cancer centers, universities, pharmaceutical and clinical researchers, and other healthcare providers. Our CLIA-certified and CAP-accredited laboratory combines a highly trained professional staff with innovative instrumentation for optimal test results and quality control. Biocept works with strategic industry leaders, as well as major cancer centers across the U.S., to further its mission of helping to improve outcomes for cancer patients. We also are utilizing our molecular diagnostic capabilities to offer nationwide RT-PCR-based COVID-19 testing and services to support public health efforts. Revenue from COVID-19 testing has supported further investment in our core oncology business, positioning the company for long-term success.